Articles tagged with Multiple Sclerosis
The Robert A. Winn Excellence in Clinical Trials Award Program is expanding its career development award to include neuropsychiatry researcher-physicians. This expansion aims to improve clinical trial enrollment and represent diverse patient populations affected by complex disorders.
Dr. Ludwig Kappos has made enormous contributions to MS research, advancing clinical trial conduct and outcome measures, and leading international collaborations. He will formally receive the award at the American Academy of Neurology Annual Meeting in Chicago on April 19, 2026.
A genetic mutation found in high-altitude animals may help regenerate myelin sheath and repair nerve damage in conditions like MS and cerebral paralysis. The mutation increases production of a metabolite that promotes myelin production and maturation.
A new study reveals that people of South Asian, African, and European ancestry share common genetic risk factors for multiple sclerosis, despite historic lack of representation in research. The study highlights the importance of diverse representation in research to improve understanding of the disease and develop effective treatments.
A study found that people with changes in their activity patterns were more likely to have worsening disability and loss of brain volume than those whose patterns did not change. Wearable sensors measure physical activity, time spent sitting or inactive, and circadian rhythms.
The International Progressive MS Alliance has funded three global studies to address common symptoms of progressive MS, such as fatigue and cognitive impairment. These Well-Being Phase II Efficacy Awards aim to develop innovative approaches for improving well-being in people with progressive MS.
Myelin swellings are precursor lesions in MS, but research reveals they have a dynamic character, growing, shrinking and recovering. The underlying nerve fibre activity plays a key role in their formation.
A global study found that a group of bacteria, CAG-170, consistently appeared in high numbers in the gut microbiomes of healthy individuals. This species has the capacity to produce Vitamin B12 and break down carbohydrates, suggesting it plays a crucial role in maintaining human health.
A new software tool developed by MIT researchers can reliably and finely resolve eight distinct nerve bundles in live diffusion MRI scans, shedding light on neurodegenerative diseases like Parkinson's and Alzheimer's. The BrainStem Bundle Tool (BSBT) reveals distinct patterns of structural changes in patients with these conditions.
Researchers found that certain types of CD8+ killer T cells are more abundant in people with MS and target the EBV virus, indicating the virus may trigger an immune response leading to progressive neurological damage. The study suggests that interfering with EBV could have a significant impact on other autoimmune diseases.
A study published in the Journal of Neurologic Physical Therapy found that backward walking training improved postural stability and gait speed in most participants with multiple sclerosis. The researchers suggest that this therapy may promote neuroplasticity and be a potential new treatment for improving mobility and decreasing falls.
Dr. Manuel A. Friese has been recognized for his groundbreaking work studying the interactions between inflammation and nerve cell death, which drives disease progression in multiple sclerosis (MS). His research aims to identify new therapeutic targets and bring the field closer to stopping disease progression.
New study finds that progenitor cells in the brain continuously produce new myelin-producing oligodendrocytes, despite being inefficient. This process suggests that treatments harnessing their developmental aspects may increase rapid myelin repair for demyelinating diseases like multiple sclerosis.
A Murdoch University review found that people with MS experience difficulties navigating society and feel ashamed about their condition. The study highlights gaps in the ICF framework, which may not capture the full emotional and social burden of living with MS.
A new study from Karolinska Institutet reveals the Epstein-Barr virus can damage the brain and contribute to multiple sclerosis through molecular mimicry. The researchers found that cross-reactive T cells are significantly more common in people with MS, and targeting these cells may lead to new treatments.
Researchers identify a concrete biological mechanism that triggers MS, focusing on B cells and Epstein-Barr virus. This understanding may help guide future strategies to prevent or treat MS.
Research reveals molecular interaction between environmental and genetic risk factors triggers MS. EBV and gene variants HLA-DR15 haplotype play key roles in disease onset.
A University of Toronto-led study has discovered a potential biomarker linked to multiple sclerosis disease progression that could help identify patients most likely to benefit from new drugs. The findings were validated in both mouse models and humans, suggesting a possible surrogate marker for leptomeningeal inflammation.
Research analyzed blood samples from 1,800 individuals in Sweden, finding links between PFAS and PCB exposure and increased odds of multiple sclerosis. The study also highlighted genetic vulnerability and complex interactions between environmental contaminants and hereditary factors.
A randomized controlled trial found that lipoic acid had a small beneficial effect on slowing brain atrophy in people with progressive multiple sclerosis. However, it did not improve walking speed as the primary clinical outcome. The study suggests that lipoic acid may be worth further investigation for its potential benefits.
Researchers discovered that a missing piece of myelin in nerve cells slows signal transmission to the thalamus, disrupting communication loops and cognitive tasks. This finding sheds light on symptoms associated with grey matter lesions in MS.
CEMIP is associated with the breakdown of myelin, a protective sheath around nerve cells. Elevated levels of the enzyme inhibit myelin regeneration in people with multiple sclerosis. Researchers hope targeting CEMIP may promote central nervous system repair and slow disease progression.
A study published in JAMA Network Open found that older adults with chronic kidney disease or cerebrovascular disease are at double the risk for developing neuroinvasive West Nile virus infection, which can lead to paralysis and death. The study identified several risk factors, including male sex, immune suppressants, and multiple scle...
Two first-in-class antibodies, C01 and C04, have been developed to inhibit inflammation in autoimmune diseases by blocking the high-affinity IgG receptor FcγRI. The antibodies were discovered using a unique immunization method and exhibit higher affinity for FcγRI than human IgG.
Researchers at the University of Illinois Chicago have developed a novel multiple sclerosis treatment that utilizes nanoparticle-boosted myeloid-derived suppressor cell therapy. This innovative approach aims to reprogram the immune system and promote tolerance in patients with MS.
Researchers created a multidimensional molecular map of brain development after birth and its response to inflammation, finding that some developmental programmes can be reactivated during neuroinflammation. This study provides new clues for understanding how myelin is broken down in diseases like MS.
A University of Houston researcher identifies a protein that may reduce high ketone levels in diabetic patients, potentially improving health outcomes. The study also shows that the protein promotes muscle ketolysis and running capacity in mice.
A UK-wide study of 5,509 people with MS found that the condition significantly affects health-related quality of life. The research used EQ-5D-5L tool to measure changes in health status, revealing varying thresholds by MS type and relapse history.
Researchers found that people with MS have a distinct oral microbiome compared to healthy individuals, characterized by a loss of beneficial bacteria and an increase in disease-causing bacteria. The study suggests that oral microbial and metabolic changes may contribute to inflammation and disease processes in MS.
Scientists analyzed thousands of proteins in blood samples to understand when multiple sclerosis attacks the myelin sheath and nerve fibers. Researchers identified a protein called IL-3, which plays a key role in this early phase of damage.
Researchers at UCLA Health have identified a sex-chromosome linked gene that drives inflammation in the female brain, making women more susceptible to conditions like Alzheimer's disease and multiple sclerosis. Deactivating this gene and using diabetes medication metformin showed promising results in reducing symptoms in female mice.
A multidisciplinary study at Texas A&M University finds that estrogens estradiol and estriol may reduce symptoms of progressive MS by decreasing inflammation in the spinal cord. Estradiol also significantly decreases damage to the myelin sheath, a protective coating around nerve fibers, making it a promising therapeutic intervention.
Researchers identify disease-associated radial glia-like cells that contribute to persistent inflammation and neurodegeneration in progressive multiple sclerosis. These cells exhibit characteristic features of radial glia and display hallmark features of premature aging, fuelling a toxic environment that accelerates neurodegeneration.
Scientists have identified two compounds, K102 and K110, that could promote remyelination and modulate immune function in multiple sclerosis. These compounds showed promising results in mouse models and human cells, suggesting potential for treating MS and possibly other neurological diseases.
A study by UC Riverside researchers identifies a strong connection between demyelination and seizure activity in multiple sclerosis. The findings suggest targeted treatments could address the root cause of seizures without suppressing overall brain activity.
The review highlights the critical roles of phospholipids in regulating immune cell migration, differentiation, and survival, as well as their regulatory effects on inflammation. Dysregulated phospholipid metabolism is linked to various diseases, including autoimmune disorders, cardiovascular disease, and cancer.
Researchers have developed a tool that can predict how patients with multiple sclerosis will respond to natalizumab treatment, allowing for targeted treatments with fewer side effects. The tool uses high-content imaging and machine learning to analyze cell morphology and identify individuals who are unlikely to respond to the medication.
New research links higher intake of ultra-processed foods to more frequent relapses and greater MRI-detected lesion activity in early multiple sclerosis. Researchers found that increased consumption was associated with disrupted gut barrier function, immune activation, and cellular energy production problems.
New research reveals that menopause may significantly influence how multiple sclerosis first presents in women, with distinct differences in symptom patterns and associated health conditions. The analysis found that postmenopausal women experienced more frequent cardiovascular disease and metabolic disorders.
A multi-registry study found ocrelizumab superior to other treatments in reducing MS relapse rates. Ocrelizumab outperformed fingolimod, natalizumab, and alemtuzumab in controlling multiple sclerosis relapses.
The American College of Chest Physicians has achieved a critical milestone in its advocacy efforts, leading to changes in federal coverage guidelines for noninvasive ventilation devices used in the home. These revised guidelines reflect major recommendations submitted by CHEST and aim to enhance patient care.
A study of Medicare database payments found that nearly 80% of US neurologists prescribing multiple sclerosis (MS) drugs received industry payments, with higher volume prescribers more likely to be beneficiaries. Recipients were also more likely to prescribe the company's drugs, especially if payments were larger and sustained.
The International Progressive MS Alliance has launched the MS Clinical and Imaging Data Resource (CIDR), providing access to anonymized data from thousands of people with MS who participated in clinical trials. The resource aims to accelerate research on progressive MS by enabling investigators to conduct more informed studies and spee...
A new study has identified a genetic biomarker that predicts which multiple sclerosis patients will respond well to treatment with glatiramer acetate. This allows for personalized therapy decisions to be made before starting treatment, with those carrying the HLA-A*03:01 gene variant showing significant clinical benefits.
A large study found that Medicare beneficiaries with multiple sclerosis who received broader coverage of MS treatments had significantly lower risk of developing new or worsening symptoms. Researchers warn that formulary exclusions for specialty drugs could lead to worse health outcomes.
People with MS show higher healthcare use up to 15 years before symptoms appear, highlighting opportunities for earlier identification and intervention. The study analyzed health records of over 12,000 people in BC and found distinct patterns of healthcare engagement before symptom onset.
A study published in Neurology found that women with multiple sclerosis are less likely to receive disease-modifying drugs than men, even when accounting for pregnancy and postpartum periods. The study suggests that women's reluctance to use these treatments may be a factor in the disparity.
A new study by University of South Australia researchers uses genetic recall to explore links between multiple sclerosis (MS) and the Epstein-Barr virus. The study aims to identify early warning signs or biomarkers for MS, enabling early detection and intervention.
A study by the University of Eastern Finland found that physical performance is associated with better cognition in people with relapsing-remitting MS. The study measured cognitive function, disability, and physical activity using various tests, revealing a significant link between these factors.
Researchers at the University of Cambridge have made a groundbreaking discovery on how neural stem cell grafts can restore myelin in MS lesions in mice. The study provides critical evidence supporting the safety and efficacy of human induced neural stem cell transplantation as a potential new treatment for progressive multiple sclerosis.
Researchers have developed a novel treatment approach for autoimmune diseases by engineering a protein that holds closely together two signaling complexes on T cells, shutting down those T cells in a limited way. This approach shows promise for treating conditions such as Type-1 diabetes and multiple sclerosis.
Researchers discovered that children with MS show signs of accelerated biological aging, even in their teenage years, which may lead to new treatment possibilities beyond immunosuppression. The study found that youth with MS had evidence of accelerated epigenetic age, a measurement of DNA chemical modifications associated with aging.
The National Multiple Sclerosis Society is offering funding opportunities for next-generation researchers and clinicians, as well as projects advancing women's health in MS. The American Brain Foundation and US Department of Defense are also providing grants for neuroinflammation research and clinical trials.
A study of twins reveals that certain bacteria in the small intestine may trigger MS. Researchers identified two specific bacteria, Lachnoclostridium sp and Eisenbergiella tayi, which are associated with the disease. The findings suggest a new potential therapeutic target for MS treatment.
A new study published in Neurology Open Access found that an MRI scan can accurately diagnose multiple sclerosis (MS) in just 8 minutes, eliminating the need for a painful spinal tap. The study's findings support the use of a T2*-weighted MRI and a 'rule of six' to confirm a diagnosis without lumbar puncture.
The National Multiple Sclerosis Society has committed $18.1 million to support research projects aligned with its Pathways to Cures roadmap, which aims to stop MS, restore function, and end the disease. The funding includes 16 research grants and 28 training fellowships in the US and internationally.
Researchers at University of Turku discovered a new biomarker that correlates the thickness of inflammatory cell rim surrounding brain lesions with disease severity and speed. The wider the rim, the more aggressively the disease advances, allowing for earlier treatment identification and evaluating drug candidates.
The International Progressive MS Alliance has awarded €100,000 to three development project teams to plan clinical trials. The projects focus on developing new treatments for progressive MS, including exercise-induced fatigability, neural stem cell therapy, and salbutamol treatment.
A new AI model developed by Uppsala University accurately diagnoses multiple sclerosis (MS) with an overall accuracy of 90%, identifying the transition from relapsing-remitting to secondary progressive MS in almost 87% of cases. This enables earlier diagnosis, reducing the risk of patients receiving ineffective medicines.
A rodent study found hnRNP A1 regulates myelin production and maintains its integrity, suggesting an impact on neurodegenerative diseases like schizophrenia. The findings provide new insights into the disease's molecular basis and potential treatments.